<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798651</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2020/71</org_study_id>
    <nct_id>NCT04798651</nct_id>
  </id_info>
  <brief_title>Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis</brief_title>
  <acronym>T4MS</acronym>
  <official_title>Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties&#xD;
      in the different clinical forms of multiple sclerosis. This research might open new&#xD;
      therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple sclerosis (MS) is a chronic autoimmune disease damaging the central nervous system&#xD;
      (CNS). MS is categorized into several distinct forms according to clinical symptoms and&#xD;
      medical examinations. Relapsing-remitting multiple sclerosis (RRMS) is characterized by&#xD;
      attacks of worsening neurologic function, followed by partial or complete recovery periods.&#xD;
      Patients can also present a gradual but steady progression of the disease (progressive&#xD;
      forms). While several treatment options are currently available, no treatment completely&#xD;
      stops the disease progression. Therefore, a deeper understanding regarding the mechanism of&#xD;
      the disease development is essential to generate more efficient treatment strategies. CD4 T&#xD;
      cells are known to be significantly involved in the formation of the CNS lesions&#xD;
      characteristic of MS.The investigators hypothesize that different types of B and CD4 T cells&#xD;
      play major roles in different forms of the disease. They will determine the phenotype and&#xD;
      functions of the cells from the immune system particularly B and CD4 T cells present in the&#xD;
      blood and cerebro-spinal fluid (CSF) of patients diagnosed with multiple sclerosis or&#xD;
      presenting a clinically isolated syndrome.&#xD;
&#xD;
      The study will recruit 150 patients followed in Bordeaux University Hospital and diagnosed&#xD;
      for clinically isolated syndrome (CIS) or multiple sclerosis (MS). Blood and CSF will be&#xD;
      collected during a scheduled visit to study the properties of cells from the immune system in&#xD;
      particular CD4 T cells in multiple sclerosis. Clinical and biological disease activity,&#xD;
      treatment and outcomes will be studied in correlation with the properties of blood and CSF&#xD;
      lymphocytes. No extra visit will be needed and the blood and CSF samples will be collected at&#xD;
      the same times as those collected for clinical purposes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional and phenotypical characterization of the blood and CSF lymphocytes in MS and CIS patients.</measure>
    <time_frame>At inclusion (day 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of disease activity scores</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>Expanded Disability Status Scale (EDSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of disease activity scores</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>ambulation test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of lesions</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>evaluated by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of lesions</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>evaluated by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Localisation of lesions</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>evaluated by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types of lesions</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>evaluated by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of the disease</measure>
    <time_frame>At inclusion (day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>age at onset and progression</measure>
    <time_frame>At inclusion (day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of relapses</measure>
    <time_frame>At inclusion (day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>date of relapses</measure>
    <time_frame>At inclusion (day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment</measure>
    <time_frame>At inclusion (day 0)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Clinically Isolated Syndrome</condition>
  <arm_group>
    <arm_group_label>patients with multiple sclerosis or clinically isolated syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation</description>
    <arm_group_label>patients with multiple sclerosis or clinically isolated syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cerebro-spinal fluid</intervention_name>
    <description>1 ml of cerebro-spinal fluid</description>
    <arm_group_label>patients with multiple sclerosis or clinically isolated syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female subjects ;&#xD;
&#xD;
          -  Age ≥ 18 years;&#xD;
&#xD;
          -  subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical&#xD;
             isolated syndrome;&#xD;
&#xD;
          -  patients for which a blood draw and / or lumbar puncture to collect CSF is performed&#xD;
             for diagnostic or therapeutic purpose;&#xD;
&#xD;
          -  affiliated to an health insurance system;&#xD;
&#xD;
          -  and who agree to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women,&#xD;
&#xD;
          -  patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty&#xD;
             by a judicial or administrative decision, minors, persons of legal age who are the&#xD;
             object of a legal protection measure or unable to express their consent)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurélie RUET, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathalie SCHMITT, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie RUET, Prof</last_name>
    <phone>05 56 79 55 21</phone>
    <phone_ext>+33</phone_ext>
    <email>aurelie.ruet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathilde DELOIRE, PhD</last_name>
    <email>mathilde.deloire@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux - service de neurologie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie RUET, Prof</last_name>
      <email>aurelie.ruet@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mathilde DELOIRE, PhD</last_name>
      <email>mathilde.deloire@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Aurélie RUET, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe OUALLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile DULAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline BUISSONNIERE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis NADAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune Diseases of the Nervous System</keyword>
  <keyword>Multiple sclerosis</keyword>
  <keyword>clinically isolated syndrome</keyword>
  <keyword>lymphoid cells</keyword>
  <keyword>CD4 T cells</keyword>
  <keyword>B cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

